摘要
目的探讨脆性组氨酸三联体基因(FHIT)在子宫内膜癌及子宫内膜不典型增生组织中的表达及其与临床意义。方法以75例子宫内膜不典型增生及75例子宫内膜癌患者作为研究组,选取60例同期正常子宫内膜组织作为对照组,采用免疫组织化学(SP)方法,检测研究组与对照组中子宫内膜组织中FHIT的表达情况。并分析FHIT表达与子宫内膜癌病理分期、组织学分级的关系。结果正常子宫内膜、子宫内膜不典型增生、子宫内膜癌组织FHIT阳性表达率分别为96.67%、57.33%、34.67%(P<0.05)。高、中、低分化子宫内膜腺癌患者FHIT阳性表达率分别为61.54%、34.04%、13.33%,三者间有显著差异(P<0.05),Ⅰ期、Ⅱ期、Ⅲ期患者FHIT表达无显著差异。轻、中、重度子宫内膜不典型增生患者FHIT阳性率分别为64.71%、57.57%、52.00%。结论 FHIT作为1种肿瘤抑制基因蛋白,可能成为临床判断子宫内膜不典型增生预后转归的预测因素。
Objective To explore the expression of FHIT in endometrial cancer and endometrial atypical hyperplasia tissues,and the realation between FHIT expression and clinicopathological factors.Methods We randomly selected 75 patients with atypical endometrial hyperplasia and 75 patients with endometrial cancer.60 cases with normal endometrium were chosen as a control group at the same period.We used immunohistochemical (SP) method to detect the expression of FHIT in endometrial tissues;we also analyzed the relationship between the expression of FHIT and pathologic staging of endometrial lesions,histological grade.Results The positive expression of FHIT was 96.67%,57.33% and 34.67% respectively in normal endometrium,endometrial hyperplasia,and endometrial cancer.Of the 75 cases with endometrial carcinoma,the FHIT expression were 61.54%,34.04%,13.33% respectively in well-differentiated,moderately differentiated,poorly differentiated endometrial adenocarcinoma patients,and the difference was statistically significant (P<0.05).The expression of FHIT in patients with stage Ⅰ,Ⅱ,and Ⅲ was 64.71%,57.57% and 52.00%,respectively,and the difference was not statistically significant.Conclusion As a tumor suppressor gene protein,FHIT protein may be served as a predictor of the prognosis in patients with endometrial hyperplasia.
出处
《实用癌症杂志》
2010年第5期476-478,共3页
The Practical Journal of Cancer
